Jennifer Buell - 05 Aug 2026 Form 4 Insider Report for AGENUS INC (AGEN)

Reporting relationship: Chairman of the Executive Counsel, Director
Issuer ticker: AGEN
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 14:07:33 UTC
Prior SEC filing: 28 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/Melissa Orilall, as Attorney-in-Fact for Jennifer Buell

Key filing fact

Jennifer Buell filed Form 4 for AGENUS INC (AGEN) on 07 Aug 2026.

Key facts

This page summarizes Jennifer Buell's Form 4 filing for AGENUS INC (AGEN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 14:07.

Change

Previous filing in this sequence was filed on 28 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001711184 Primary reporting owner

Buell Jennifer

Relationship: Chairman of the Executive Counsel, Director
Address: C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON
Signature: /s/Melissa Orilall, as Attorney-in-Fact for Jennifer Buell
Signature date: 07 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGEN transaction Derivative

Stock Option

Award

Transaction value
Shares: +200,000
Change %
Price: $0.000000^*
Shares after: 200,000
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $7.78
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC remarks

Chairman of the Executive Counsel